碧生源(00926.HK)年度純利跌71.99%至4547.9萬元 末期息3.75港仙
格隆匯 3 月 12日丨碧生源(00926.HK)發佈年度業績,截至2020年12月31日止年度,公司收入為人民幣12.93億元,同比增長59.17%;毛利為人民幣9.13億元,同比增長56.27%,毛利率降至70.7%;公司擁有人應占溢利為人民幣4547.9萬元,同比減少71.99%;每股基本盈利為人民幣2.85分,擬派末期息每股3.75港仙。
收入上升主要得益於產品的多元化,以及電商渠道的深耕及其他銷售渠道的擴展帶來的各類產品的銷量增加。
其中,增長尤其明顯的是減肥藥品及其他產品及藥品兩個分部。2019年減肥藥品的收入為人民幣3.245億元,2020年收入上升87.1%至人民幣6.073億元。2019年其他產品及藥品的收入為人民幣6250萬元,2020年收入則上升220.2%至人民幣2.001億元。
減肥藥品和其他產品及藥品的收入佔比分別從2019年的40.0%和7.7%提升到2020年的47.0%和15.5%。碧生源牌常潤茶和碧生源牌常菁茶的銷售收入佔比分別從2019年的21.7%和22.9%下降至2020年的14.8%和15.4%。
此外,集團的研究及開發成本由2019年的人民幣4740萬元上升97.9%至2020年的人民幣9380萬元,主要是藥品部分加大了自主研發力度及增加了委外研發所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.